Key facts
- Precision Cardiovascular’s last known valuation is $2.9M (Apr 2022).
- It has raised $1.0M; the latest was Seed Round in May 2025.
- Notable investors include Innovate UK, 500 Global, Acasia Group, Arige Ali, Imperial College London.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Precision Cardiovascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Precision Cardiovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Precision Cardiovascular
Developer of micro-sensor technology designed for the early detection of cardiovascular complications. The company's technology provides data to visualize patient conditions, the evolution of their illness, and the effectiveness of therapy while automating clinical workflow, enabling care providers to refine drug dosing, expand therapeutic insights, and conduct preventative measures.
- Sector
- Healthcare
- HQ
- Uxbridge, United Kingdom
- Founded
- 2021
- Employees
- 7
- Website
- precision-cv.com/
- Ownership
- Privately Held (backing)
Precision Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precision Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precision Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.